RCT | Single-dose Acoziborole is effective and safe for patients with sleeping sickness.

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial – The Lancet Infectious Diseases

News Release: New single-dose treatment for sleeping sickness could help eliminate transmission of the disease by 2030 – The Lancet

Commentary: Single dose of acoziborole 95% effective in treating sleeping sickness – CIDRAP